MBVax Bioscience is reintroducing Coley Fluid, an historical therapy for cancer and other diseases.  

MBVax Coley Fluid is not approved by regulators and therefore is not available in Canada or the United States, except in the context of authorized clinical trials. The company is working towards conducting clinical trials in Canada and the United States. The timing for such possible trials is uncertain at this time.  

As of August 2007, 38 advanced cancer patients have received between 3 weeks and 10 months MBVax Coley Fluid therapy. Most patients in this series had severely compromised immune systems due to previous therapies. Even so, in 24 of 38 patients there was apparent regression of cancer, and in 36 of 38 patients there were quality of life improvements including reduction or disappearance of cancer pain, increased mobility and weight gain.